KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Aesthetic Improvements Over Time: Long-Term Efficacy and Additional Outcomes of IncobotulinumtoxinA in the Simultaneous Treatment of Upper Facial Lines.

Tatjana Pavicic, Cheryl Burgess, Sabrina Fabi, Mark S Nestor, Eva Kristina Bee, Matthias Imhof, Hanna Dersch, Vladimir Sudimac

J Cosmet Dermatol 24(9) e70460

PMID40968493
PMCIDPMC12446747
DOI10.1111/jocd.70460
发表日期2025-09-19
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。
摘要

摘要

BACKGROUND/OBJECTIVES: Two Phase III randomized controlled trials were conducted in the US (ULTRA I) and Germany (ULTRA II) to investigate the efficacy of incobotulinumtoxinA for simultaneous treatment of upper facial lines (UFLs: glabellar frown lines [GFLs], horizontal forehead lines [HFLs] and lateral canthal lines [LCLs]). PATIENTS/METHODS: Healthy adults with moderate to severe GFLs, HFLs, and symmetrical LCLs were enrolled. Participants were randomized 2:1:1 to three groups: placebo, UFLs, and GFLs & HFLs (ULTRA I) or LCLs (ULTRA II). All participants received up to 64 units of incobotulinumtoxinA in the main period (MP) and were eligible for two additional treatment cycles in the open-label extensions (OLEX). Endpoints included participant- and investigator-assessed Global Aesthetic Improvement Scale (pGAIS and iGAIS, respectively; any improvement defined as ≥ +1 score versus baseline) and the percentage of GFL, HFL, and LCL responders, defined as ≥ 1-grade improvement in Merz Aesthetics Scale (MAS) score versus baseline at maximum contraction. RESULTS: For pGAIS at Day 30, the proportion of participants with any improvement was very high (> 97%) across all three treatment cycles. iGAIS results were similar and slightly higher than pGAIS results. In the MP, investigator and participant MAS assessments were similar, with > 78% of participants showing a positive treatment response for UFLs up to Day 90; responses in the placebo groups remained low at all time points (< 13%). MAS results in the OLEX were consistent with the MP. CONCLUSIONS: Additional endpoints, including pGAIS, iGAIS, and MAS scores, corroborate prior ULTRAI/II findings and demonstrate the efficacy of incobotulinumtoxinA for simultaneous treatment of UFLs. TRIAL REGISTRATION: ULTRA I: NCT04594213; ULTRA II: NCT04622254.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 GAIS, “any improvement” a over ULTRA I MP. This figure presents the rate of participants with “any improvement” a on the GAIS in the MP of ULTRA I, as assessed by the participant (above, purple) and investigator (below, blue). To see the contrast with the placebo group, all participants who received treatment are presented as “Group U and G&H combined.” Analysis is based on observed cases in the full analysis set. a Score of at least +1. GAIS, Global Aesthetic Improvement Scale; Group G&H, treatment of glabellar frown lines and horizontal forehead lines and placebo treatment of lateral canthal lines; Group P, placebo group; Group U, upper facial lines (a combination of glabellar frown lines and horizontal forehead lines and lateral canthal lines) treated; MP, main period; N , number of participants in respective analysis set.
非 KM Figure
FIGURE 2FIGURE 2 GAIS, “any improvement” a over ULTRA II MP. This figure presents the rate of participants with “any improvement” a on the GAIS in the MP of ULTRA II, as assessed by the participant (above, purple) and investigator (below, blue). To see the contrast with the placebo group, all participants who received treatment are presented as “Group U and L combined”. Analysis is based on observed cases in the full analysis set. a Score of at least +1. GAIS, Global Aesthetic Improvement Scale; Group L, treatment of lateral canthal lines; Group P, placebo group; Group U, upper facial lines (a combination of glabellar frown lines and horizontal forehead lines and lateral canthal lines) treated; MP; main period; N , number of participants in respective analysis set.
非 KM Figure
FIGURE 3FIGURE 3 GAIS, “any improvement” a over ULTRA I/II OLEX. This figure presents the rate of participants with “any improvement” a on the GAIS in the OLEXs of ULTRA I/II, as assessed by the participant (above, green) and investigator (below, blue). As treatment was open‐label, participants were pooled into one treatment group. Analysis is based on observed cases in the full analysis set. a Score of at least +1. GAIS, Global Aesthetic Improvement Scale; N , number of participants in respective analysis set; OLEX, open‐label extension period.
非 KM Figure
FIGURE 4FIGURE 4 Representative photographs of one participant from Group U at maximum contraction at baseline, Day 30 of the MP and final OLEX visit (Cycle 3, Day 120). This figure shows photographs of a participant initially randomized to Group U, at maximum contraction for each respective treatment area (GFLs, HFLs and LCLs). Photos are from baseline, Day 30 of the MP and the final OLEX visit, following a total of 3 treatment cycles. GFL, glabellar frown lines; HFL, horizontal forehead lines; LCL, lateral canthal lines; MP, main period; OLEX, open‐label extension.
非 KM Figure